{
    "xml": "<topic id=\"PHP5536\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/imatinib\" basename=\"imatinib\" title=\"IMATINIB\">\n<title>IMATINIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_933\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/imatinib\">Imatinib</xref>\n</p>\n<data name=\"vtmid\">391634008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_208007314\" title=\"Protein kinase inhibitors\">Protein kinase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP61420\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/imatinib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Imatinib is a tyrosine kinase inhibitor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61353\" outputclass=\"indicationsAndDose\" rev=\"1.34\" parent=\"/drugs/imatinib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of chronic myeloid leukaemia in chronic phase after failure with interferon alfa</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>400&#8239;mg once daily, increased if necessary up to 800&#8239;mg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of chronic myeloid leukaemia in accelerated phase, or in blast crisis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;mg once daily, then increased if necessary up to 800&#8239;mg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of newly diagnosed acute lymphoblastic leukaemia (in combination with other chemotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Monotherapy for relapsed or refractory acute lymphoblastic leukaemia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST)</p>\n<p outputclass=\"therapeuticIndication\">Adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse</p>\n<p outputclass=\"therapeuticIndication\">Treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>400&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of unresectable dermatofibrosarcoma protuberans</p>\n<p outputclass=\"therapeuticIndication\">Recurrent or metastatic dermatofibrosarcoma protuberans, in patients who cannot have surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>800&#8239;mg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8211;400&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61429\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/imatinib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61449\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/imatinib\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cardiac disease</ph>; <ph outputclass=\"caution\">history of renal failure</ph>; <ph outputclass=\"caution\">risk factors for heart failure</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61333\" outputclass=\"interactions\" rev=\"1.14\" parent=\"/drugs/imatinib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (imatinib).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61208\" outputclass=\"sideEffects\" rev=\"1.25\" parent=\"/drugs/imatinib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">appetite changes</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">ascites</ph>; <ph outputclass=\"sideEffect\">conjunctivitis</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">cramps</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dry eyes</ph>; <ph outputclass=\"sideEffect\">dry mouth</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">gastro-oesophageal reflux</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypoaesthesia</ph>; <ph outputclass=\"sideEffect\">increased lacrimation</ph>; <ph outputclass=\"sideEffect\">influenza-like symptoms</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">photosensitivity</ph>; <ph outputclass=\"sideEffect\">pleural effusion</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">pulmonary oedema</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>; <ph outputclass=\"sideEffect\">weight changes</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acute respiratory failure</ph>; <ph outputclass=\"sideEffect\">anxiety</ph>; <ph outputclass=\"sideEffect\">cold extremities</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dysphagia</ph>; <ph outputclass=\"sideEffect\">electrolyte disturbances</ph>; <ph outputclass=\"sideEffect\">gastric ulceration</ph>; <ph outputclass=\"sideEffect\">gout</ph>; <ph outputclass=\"sideEffect\">gynaecomastia</ph>; <ph outputclass=\"sideEffect\">haematoma</ph>; <ph outputclass=\"sideEffect\">hearing loss</ph>; <ph outputclass=\"sideEffect\">heart failure</ph>; <ph outputclass=\"sideEffect\">hepatic dysfunction</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">impaired memory</ph>; <ph outputclass=\"sideEffect\">irregular menstruation</ph>; <ph outputclass=\"sideEffect\">menorrhagia</ph>; <ph outputclass=\"sideEffect\">migraine</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">renal failure</ph>; <ph outputclass=\"sideEffect\">sexual dysfunction</ph>; <ph outputclass=\"sideEffect\">skin hyperpigmentation</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>; <ph outputclass=\"sideEffect\">tinnitus</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">urinary frequency</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angina</ph>; <ph outputclass=\"sideEffect\">angioedema</ph>; <ph outputclass=\"sideEffect\">arrhythmia</ph>; <ph outputclass=\"sideEffect\">aseptic necrosis of bone</ph>; <ph outputclass=\"sideEffect\">atrial fibrillation</ph>; <ph outputclass=\"sideEffect\">cataract</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">convulsions</ph>; <ph outputclass=\"sideEffect\">exfoliative dermatitis</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal perforation</ph>; <ph outputclass=\"sideEffect\">glaucoma</ph>; <ph outputclass=\"sideEffect\">haemolytic anaemia</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">hepatic necrosis</ph>; <ph outputclass=\"sideEffect\">increased intracranial pressure</ph>; <ph outputclass=\"sideEffect\">inflammatory bowel disease</ph>; <ph outputclass=\"sideEffect\">intestinal obstruction</ph>; <ph outputclass=\"sideEffect\">myocardial infarction</ph>; <ph outputclass=\"sideEffect\">myopathy</ph>; <ph outputclass=\"sideEffect\">pulmonary fibrosis</ph>; <ph outputclass=\"sideEffect\">pulmonary hypertension</ph>; <ph outputclass=\"sideEffect\">rhabdomyolysis</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">drug rash with eosinophilia and systemic symptoms (DRESS)</ph>; <ph outputclass=\"sideEffect\">growth retardation in children</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61438\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/imatinib\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended). Effective contraception required during treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61314\" outputclass=\"pregnancy\" parent=\"/drugs/imatinib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61453\" outputclass=\"breastFeeding\" parent=\"/drugs/imatinib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61410\" outputclass=\"hepaticImpairment\" parent=\"/drugs/imatinib\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Max. 400&#8239;mg daily; reduce dose further if not tolerated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61264\" outputclass=\"renalImpairment\" parent=\"/drugs/imatinib\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Maximum starting dose 400&#8239;mg daily if creatinine clearance less than 60&#8239;mL/minute; reduce dose further if not tolerated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61086\" outputclass=\"monitoringRequirements\" parent=\"/drugs/imatinib\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for gastrointestinal haemorrhage.</p>\n<p>Monitor complete blood counts regularly.</p>\n<p>Monitor for fluid retention.</p>\n<p>Monitor liver function.</p>\n<p>Monitor growth in children (may cause growth retardation).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61486\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/drugs/imatinib\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Tablets may be dispersed in water or apple juice.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61292\" outputclass=\"patientAndCarerAdvice\" rev=\"1.15\" parent=\"/drugs/imatinib\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer imatinib tablets.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60961\" outputclass=\"nationalFunding\" rev=\"1.45\" parent=\"/drugs/imatinib\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA70</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Imatinib for chronic myeloid leukaemia (October 2003)</p>\r\n<p>Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA70\">www.nice.org.uk/TA70</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA86</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004)</p>\r\n<p>Imatinib 400&#8239;mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment [as defined by Southwest Oncology Group criteria available at <xref format=\"html\" href=\"http://www.nice.org.uk/TA86\">www.nice.org.uk/TA86</xref>] is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA86\">www.nice.org.uk/TA86</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA209</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Imatinib for the treatment of unresectable and/&#8239;or metastatic gastro-intestinal stromal tumours (November 2010)</p>\r\n<p>Imatinib 600&#8239;mg daily or 800&#8239;mg daily is <b>not</b> recommended for unresectable or metastatic, or both, gastro-intestinal stromal tumours whose disease has progressed after treatment with imatinib 400&#8239;mg daily.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA209\">www.nice.org.uk/TA209</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA241</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</p>\r\n<p>High-dose imatinib is <b>not </b>recommended for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA241\">www.nice.org.uk/TA241</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA251</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</p>\r\n<p>Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA251\">www.nice.org.uk/TA251</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA326</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (November 2014)</p>\r\n<p>Imatinib is recommended as an option for adjuvant treatment of adult patients who are at high risk of relapse after surgery for KIT (CD117)-positive gastro-intestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location, and mitotic rate), for up to 3 years.</p>\r\n<p>Patients currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA326\">www.nice.org.uk/TA326</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2002) that imatinib (<i>Glivec</i>\r\n<tm tmtype=\"reg\"/>) should be used for chronic myeloid leukaemia only under specialist supervision in accordance with British Society of Haematology guidelines (November 2001).</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has also advised (February 2012) that imatinib (<i>Glivec</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of adult patients who are at significant risk of relapse following resection of a KIT (CD117) positive gastrointestinal stromal tumour (GIST) and who are at high risk of recurrence following complete resection (according to the Armed Forces Institute of Pathology (AFIP) risk criteria).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5536-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/imatinib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75630\" title=\"Tablet\" namespace=\"/drugs/imatinib/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_933\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/imatinib\" title=\"Imatinib\" count=\"1\" rel=\"link\">Imatinib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75630\" namespace=\"/drugs/imatinib/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP5536",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/imatinib",
    "basename": "imatinib",
    "title": "IMATINIB",
    "interactants": [
        {
            "id": "bnf_int_933",
            "label": "Imatinib"
        }
    ],
    "vtmid": "391634008",
    "drugClassification": [
        "Protein kinase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Imatinib is a tyrosine kinase inhibitor.",
                "html": "<p>Imatinib is a tyrosine kinase inhibitor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of chronic myeloid leukaemia in chronic phase after failure with interferon alfa",
                        "html": "Treatment of chronic myeloid leukaemia in chronic phase after failure with interferon alfa"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "400 mg once daily, increased if necessary up to 800 mg daily in 2 divided doses.",
                        "html": "<p>400&#8239;mg once daily, increased if necessary up to 800&#8239;mg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of chronic myeloid leukaemia in accelerated phase, or in blast crisis",
                        "html": "Treatment of chronic myeloid leukaemia in accelerated phase, or in blast crisis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "600 mg once daily, then increased if necessary up to 800 mg daily in 2 divided doses.",
                        "html": "<p>600&#8239;mg once daily, then increased if necessary up to 800&#8239;mg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of newly diagnosed acute lymphoblastic leukaemia (in combination with other chemotherapy)",
                        "html": "Treatment of newly diagnosed acute lymphoblastic leukaemia (in combination with other chemotherapy)"
                    },
                    {
                        "textContent": "Monotherapy for relapsed or refractory acute lymphoblastic leukaemia",
                        "html": "Monotherapy for relapsed or refractory acute lymphoblastic leukaemia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "600 mg once daily.",
                        "html": "<p>600&#8239;mg once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST)",
                        "html": "Treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST)"
                    },
                    {
                        "textContent": "Adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse",
                        "html": "Adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse"
                    },
                    {
                        "textContent": "Treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement",
                        "html": "Treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "400 mg once daily.",
                        "html": "<p>400&#8239;mg once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of unresectable dermatofibrosarcoma protuberans",
                        "html": "Treatment of unresectable dermatofibrosarcoma protuberans"
                    },
                    {
                        "textContent": "Recurrent or metastatic dermatofibrosarcoma protuberans, in patients who cannot have surgery",
                        "html": "Recurrent or metastatic dermatofibrosarcoma protuberans, in patients who cannot have surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "800 mg daily in 2 divided doses.",
                        "html": "<p>800&#8239;mg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia",
                        "html": "Treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "100&#8211;400 mg once daily.",
                        "html": "<p>100&#8211;400&#8239;mg once daily.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cardiac disease",
                "html": "Cardiac disease"
            },
            {
                "type": "cautions",
                "textContent": "history of renal failure",
                "html": "history of renal failure"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for heart failure",
                "html": "risk factors for heart failure"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (imatinib).",
                "html": "<p>Appendix 1 (imatinib).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "appetite changes",
                        "html": "appetite changes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "ascites",
                        "html": "ascites",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctivitis",
                        "html": "conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cramps",
                        "html": "cramps",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry eyes",
                        "html": "dry eyes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry mouth",
                        "html": "dry mouth",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-oesophageal reflux",
                        "html": "gastro-oesophageal reflux",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypoaesthesia",
                        "html": "hypoaesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increased lacrimation",
                        "html": "increased lacrimation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "influenza-like symptoms",
                        "html": "influenza-like symptoms",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "photosensitivity",
                        "html": "photosensitivity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pleural effusion",
                        "html": "pleural effusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pulmonary oedema",
                        "html": "pulmonary oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight changes",
                        "html": "weight changes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Acute respiratory failure",
                        "html": "Acute respiratory failure",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "anxiety",
                        "html": "anxiety",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cold extremities",
                        "html": "cold extremities",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dysphagia",
                        "html": "dysphagia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "electrolyte disturbances",
                        "html": "electrolyte disturbances",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastric ulceration",
                        "html": "gastric ulceration",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gout",
                        "html": "gout",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gynaecomastia",
                        "html": "gynaecomastia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "haematoma",
                        "html": "haematoma",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hearing loss",
                        "html": "hearing loss",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "heart failure",
                        "html": "heart failure",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hepatic dysfunction",
                        "html": "hepatic dysfunction",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "impaired memory",
                        "html": "impaired memory",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "irregular menstruation",
                        "html": "irregular menstruation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "menorrhagia",
                        "html": "menorrhagia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "migraine",
                        "html": "migraine",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "renal failure",
                        "html": "renal failure",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "sexual dysfunction",
                        "html": "sexual dysfunction",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "skin hyperpigmentation",
                        "html": "skin hyperpigmentation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "tinnitus",
                        "html": "tinnitus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "urinary frequency",
                        "html": "urinary frequency",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Angina",
                        "html": "Angina",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "angioedema",
                        "html": "angioedema",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "arrhythmia",
                        "html": "arrhythmia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "aseptic necrosis of bone",
                        "html": "aseptic necrosis of bone",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "atrial fibrillation",
                        "html": "atrial fibrillation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "cataract",
                        "html": "cataract",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "convulsions",
                        "html": "convulsions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "exfoliative dermatitis",
                        "html": "exfoliative dermatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "gastro-intestinal perforation",
                        "html": "gastro-intestinal perforation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "glaucoma",
                        "html": "glaucoma",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "haemolytic anaemia",
                        "html": "haemolytic anaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hepatic necrosis",
                        "html": "hepatic necrosis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "increased intracranial pressure",
                        "html": "increased intracranial pressure",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "inflammatory bowel disease",
                        "html": "inflammatory bowel disease",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "intestinal obstruction",
                        "html": "intestinal obstruction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "myocardial infarction",
                        "html": "myocardial infarction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "myopathy",
                        "html": "myopathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pulmonary fibrosis",
                        "html": "pulmonary fibrosis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pulmonary hypertension",
                        "html": "pulmonary hypertension",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rhabdomyolysis",
                        "html": "rhabdomyolysis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drug rash with eosinophilia and systemic symptoms (DRESS)",
                        "html": "drug rash with eosinophilia and systemic symptoms (DRESS)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "growth retardation in children",
                        "html": "growth retardation in children",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended). Effective contraception required during treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended). Effective contraception required during treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs risk.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs risk.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Max. 400 mg daily; reduce dose further if not tolerated.",
                "html": "<p>Max. 400&#8239;mg daily; reduce dose further if not tolerated.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Maximum starting dose 400 mg daily if creatinine clearance less than 60 mL/minute; reduce dose further if not tolerated.",
                "html": "<p>Maximum starting dose 400&#8239;mg daily if creatinine clearance less than 60&#8239;mL/minute; reduce dose further if not tolerated.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for gastrointestinal haemorrhage.\n\nMonitor complete blood counts regularly.\n\nMonitor for fluid retention.\n\nMonitor liver function.\n\nMonitor growth in children (may cause growth retardation).",
                "html": "<p>Monitor for gastrointestinal haemorrhage.</p><p>Monitor complete blood counts regularly.</p><p>Monitor for fluid retention.</p><p>Monitor liver function.</p><p>Monitor growth in children (may cause growth retardation).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Tablets may be dispersed in water or apple juice.",
                "html": "<p>Tablets may be dispersed in water or apple juice.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer imatinib tablets.",
                "html": "<p>Patients or carers should be given advice on how to administer imatinib tablets.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA70",
                        "label": "www.nice.org.uk/TA70"
                    }
                ],
                "fundingIdentifier": "NICE TA70",
                "textContent": "Imatinib for chronic myeloid leukaemia (October 2003) Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously.\n\nwww.nice.org.uk/TA70",
                "html": "<p outputclass=\"title\">Imatinib for chronic myeloid leukaemia (October 2003)</p> <p>Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA70\">www.nice.org.uk/TA70</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA86",
                        "label": "www.nice.org.uk/TA86"
                    },
                    {
                        "id": "http://www.nice.org.uk/TA86",
                        "label": "www.nice.org.uk/TA86"
                    }
                ],
                "fundingIdentifier": "NICE TA86",
                "textContent": "Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004) Imatinib 400 mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment [as defined by Southwest Oncology Group criteria available at www.nice.org.uk/TA86] is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond.\n\nwww.nice.org.uk/TA86",
                "html": "<p outputclass=\"title\">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004)</p> <p>Imatinib 400&#8239;mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment [as defined by Southwest Oncology Group criteria available at <xref format=\"html\" href=\"http://www.nice.org.uk/TA86\">www.nice.org.uk/TA86</xref>] is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA86\">www.nice.org.uk/TA86</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA209",
                        "label": "www.nice.org.uk/TA209"
                    }
                ],
                "fundingIdentifier": "NICE TA209",
                "textContent": "Imatinib for the treatment of unresectable and/ or metastatic gastro-intestinal stromal tumours (November 2010) Imatinib 600 mg daily or 800 mg daily is not recommended for unresectable or metastatic, or both, gastro-intestinal stromal tumours whose disease has progressed after treatment with imatinib 400 mg daily.\n\nwww.nice.org.uk/TA209",
                "html": "<p outputclass=\"title\">Imatinib for the treatment of unresectable and/&#8239;or metastatic gastro-intestinal stromal tumours (November 2010)</p> <p>Imatinib 600&#8239;mg daily or 800&#8239;mg daily is <b>not</b> recommended for unresectable or metastatic, or both, gastro-intestinal stromal tumours whose disease has progressed after treatment with imatinib 400&#8239;mg daily.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA209\">www.nice.org.uk/TA209</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA241",
                        "label": "www.nice.org.uk/TA241"
                    }
                ],
                "fundingIdentifier": "NICE TA241",
                "textContent": "Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012) High-dose imatinib is not recommended for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib.\n\nwww.nice.org.uk/TA241",
                "html": "<p outputclass=\"title\">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</p> <p>High-dose imatinib is <b>not </b>recommended for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA241\">www.nice.org.uk/TA241</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA251",
                        "label": "www.nice.org.uk/TA251"
                    }
                ],
                "fundingIdentifier": "NICE TA251",
                "textContent": "Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012) Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).\n\nwww.nice.org.uk/TA251",
                "html": "<p outputclass=\"title\">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</p> <p>Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA251\">www.nice.org.uk/TA251</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA326",
                        "label": "www.nice.org.uk/TA326"
                    }
                ],
                "fundingIdentifier": "NICE TA326",
                "textContent": "Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (November 2014) Imatinib is recommended as an option for adjuvant treatment of adult patients who are at high risk of relapse after surgery for KIT (CD117)-positive gastro-intestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location, and mitotic rate), for up to 3 years. Patients currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA326",
                "html": "<p outputclass=\"title\">Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (November 2014)</p> <p>Imatinib is recommended as an option for adjuvant treatment of adult patients who are at high risk of relapse after surgery for KIT (CD117)-positive gastro-intestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location, and mitotic rate), for up to 3 years.</p> <p>Patients currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA326\">www.nice.org.uk/TA326</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75630",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_933",
                "label": "Imatinib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75630",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}